Bank of America CEO: Company Spends Over $350 Million Annually on GLP-1 Drugs for Employees

Bank of America is spending more than $250 million annually to provide employees with GLP-1 medications, such as Wegovy and Mounjaro, for weight loss and health improvement. CEO Brian Moynihan revealed the significant investment in a recent interview, emphasizing the positive impact these drugs are having on the company's 211,000-strong workforce.

"We are seeing a big effect on our employees," Moynihan told CNBC, noting that the cost, which was non-existent four to five years ago, is considered a worthwhile investment. He pointed out that beyond weight management, these drugs can also lower risks associated with conditions like heart disease. Moynihan stressed that the benefits are valuable even if some employees leave the company before experiencing the full long-term effects of the treatment.

“

We are seeing a big effect on our employees.

Bank of America is combining access to these medications with health coaching to support employees in their weight loss journeys and encourage lifestyle changes. However, such comprehensive benefits are not widespread. Moynihan acknowledged that some large U.S. companies have ceased covering these medications due to the substantial costs involved.

The CEO's comments underscore a growing trend among major corporations to invest in employee wellness programs that include cutting-edge pharmaceutical treatments. While the financial outlay is considerable, Bank of America appears to view it as a strategic investment in its human capital, aiming for improved overall employee health and productivity.

“

It is a worthwhile thing even if some employees leave the company before seeing the long-term effects of treatment.